ABSTRACT
Objective To establish HPLC assaying methods for the determination of albiflorin in the Jinsha-Paishi infusion, and to determine the content of albiflorin of different batches ofJinsha-Paishiinfusion. Methods The chromatographic conditions were with the column of C18 (250 mm × 4.6 mm, 5μm), mobile phase of methyl alcohol-aqua (25:75,V/V), flow rate of 1.0 ml/min, and determined at wave length of 230 nm in room temperature. A total of 3 different batches of albiflorin were determined.Results In the range of 2.5-200μg, the distribution of paeoniflorin was linear (r=0.999 8), and theRSD of precision, stability and repeatability were less than 2%. The average recovery was 98.05%, andRSD was 1.65%. The contents of albiflorin in each batch were 0.080, 0.083, 0.077 mg/g.Conclusion The assaying method of HPLC is convenient, accurate and reliable to determinate the content of albiflrin in theJinsha-Paishi infusion. And the results showed that there was no difference of content of albiflorin among the different batches ofJinsha-Paishi infusion.
ABSTRACT
Objective To observe the targeting effect of curcumin gelatin microsphere in rats in vivo. Methods Injections of curcumin gelatin microsphere and curcumin were injected via tail vein, respectively. HPLC was used to determine the content of curcumin in different organs. The pharmacokinetic parameters were calculated on the basis of compartment models by using DAS 2. 0 program. Targeting efficiency was used to evaluate tissue distribution of curcumin. Results Targeting efficiency of curcumin gelatin microsphere in heart, liver, spleen, lung and kidney was 0. 875, 0. 121, 1. 182, 5. 834 and 0. 896, respectively. Conclusion Curcumine gelatin microspheres can improve lung-targeting efficiency, and benefit for study on lung targeting therapeutic effect.
ABSTRACT
Batifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPIIb/IIIa antagonist which may be useful in the treatment and prevention of acute coronary syndromes. The pharmacokinetics and pharmacodymanic (inhibition of platelet aggregation) effects, and tolerability of batifiban were investigated in healthy subjects following single bolus injection with doses of 55, 110, or 220 microg/kg, or multiple doses of an bolus followed intravenous infusion for 24 h (180 microg/kg plus 2.0 microg/min.kg, and 220 microg/kg plus 2.5 microg/min.kg) in this phase I clinical trial. Plasma levels of batifiban and areas under the curve were found to be proportional to doses. Batifiban was rapidly eliminated with a half-life of approximately 2.5 h. Significant differences were noted for plasma levels of batifiban and areas under the curve between males and females. No significant differences in the terminal half-life were found between males and females. Batifiban reversibly inhibited ex vivo platelet aggregation in a dose- and concentration-dependent manner, consistent with its mechanism as a GPIIb/IIIa antagonist. Single and multiple intravenous doses of batifiban were found to be safe and well tolerated in healthy subjects. These results support a bolus injection plus intravenous infusion regimen of batifiban for the treatment and prevention of acute coronary syndromes.
Subject(s)
Young Adult , Injections, Intravenous , Peptides, Cyclic/pharmacokinetics , Peptides, Cyclic/pharmacology , Platelet Aggregation Inhibitors/adverse effects , Platelet Aggregation Inhibitors/pharmacokinetics , Platelet Aggregation Inhibitors/pharmacology , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitorsABSTRACT
The current study was designed to determine the safety, tolerability and pharmacokinetic parameters of recombinant human parathyroid hormone [rhPTH (1-84)] used for the treatment of osteoporosis. In the single-dose format pharmacokinetic study, thirty-six healthy male volunteers received three dose levels of rhPTH (1-84) subcutaneously: 1, 2, and 4 mug/kg. The blood was timing drawn and the serum concentration of rhPTH (1-84) was determined by enzyme linked immunosorbent assay (ELISA). Serum concentration-time curves of PTH (1-84) exhibited a double-peak pattern, the first peak appearing about 10 to 30 min after administration and the second peak occurring about 1.5 to2 h after administration. Serum terminal half-time of PTH (1-84) was approximately 2 h. The parameters indicated the serum levels were directly proportional to the administered dose, with the mean C(max) and AUC(0-24) ranging from approximately 543.47 to 1845 pg/mL and 2358.6 to 9232.12 pg.h.mL(-1) over the dose range. The drug was well tolerated, the clinical symptoms were generally mild and of short duration.
ABSTRACT
OBJECTIVE: To establish RP-HPLC method for the content determination of chlorogenic acid in 3 kinds of dosage forms of Qingkailing preparation. METHODS: SinoChrom ODS-AP C18(250 mm?4.6 mm, 5 ?m) column was adopted and the mobile phase consisted of methnol-water-acetic acid (25 ∶ 75 ∶ 0.5) at the flow rate of 1.0 mL?min-1. Column temperature was set at 30 ℃ and the detection wavelength was set at 327 nm. RESULTS: The linear range of chlorogenic acid was 3.81～152.50 ?g?mL-1(r=0.999 8), and the average recoveries of the capsules, granules and dripping pills were 99.03%(RSD=2.02%), 99.35%(RSD=1.16%),98.11%(RSD=1.51%). CONCLUSION: The method is sensitive, simple and accurate for the quality control and content determination of 3 kinds of Qingkailing preparations.
ABSTRACT
OBJECTIVE:To study the relative bioavailability and pharmacokinetics of Mycophenolate mofetil capsules vs.Mycophenolate mofetil soft capsules in healthy volunteers.METHODS:In double period randomized crossover study,20 healthy volunteers were given a single oral dose of trial capsule and reference capsule 4 pills(0.25 g per pill).The concentration of mycophenolate(MPA) was determined by HPLC.Pharmacokinetic parameters were calculated using DAs 2.0 software and the bioequivalence of 2 formulations were evaluated.RESULTS:Main pharmacokinetic parameters of trial capsule vs.reference capsule were as follows:AUC0→t:(69.95?14.13)?g?h?mL-1 vs.(66.95?19.05)?g?h?mL-1;AUC0→∞:(85.18?20.51)?g?h?mL-1 vs.(77.39?23.78) ?g?h?mL-1;Cmax:(31.26?13.09)?g?mL-1 vs.(31.90?14.45)?g?mL-1;tmax:(0.875?0.358)h vs.(0.775?0.291)h.The relative bioavailability of Mycophenolate mofetil soft capsules in 20 healthy volunteers was(109.6?26.9)%.CONCLUSION:Results of study indicated the 2 formulations are bioequivalent.
ABSTRACT
OBJECTIVE:To study the pharmacokinetics and relative bioavailability of two kinds of preparations of valaciclovir hydrochloride.METHODS:This was a randomized two-way cross-over study.A total of 18 healthy volunteers were randomly assigned to receive single oral dose of test valaciclovir tablets(trial group) or reference valaciclovir tablets(control group),with the plasma aciclovir concentrations determined by HPLC,the pharmacokinetics parameters calculated and the relative bioavailability evaluated using 3p97 program.RESULTS:The main pharmacokinetic parameters test and reference valaciclovir hydrochloride tablets were as follows:AUC0～ 24:(12.85? 4.32) vs.(12.19? 4.63) ?g? h? mL-1;AUC0～ ∞:(14.65? 5.75) vs.(13.27? 5.03) ?g? h? mL-1;Cmax:(3.55? 0.92) vs.(3.71? 0.97) ?g? mL-1;tmax:(1.44? 0.43) h vs.(1.33? 0.37) h;t1/2:(6.23? 2.81) h and(4.55? 1.84) h.The relative bioavailability of the test valaciclovir tablets were(111.01? 23.52) %.CONCLUSION:The reference valaciclovir tablets and the test valaciclovir tablets were bioequivalent.
ABSTRACT
0.05) . CONCLUSION: Gatifloxacin has no significant influence on pharmacokinetics of the hepatic injury model group as compared with the normal group.